Abstract：
UNASSIGNED: Prurigo nodularis (PN) is a chronic inflammatory skin condition that presents with pruritus and hyperkeratotic nodules. These symptoms impact patients\' quality of life and mental health. Treating prurigo nodularis is challenging, and many of the available topical and systemic therapies have limited efficacy and a myriad of adverse effects.
UNASSIGNED: In this article, we discuss the use of dupilumab for adult patients with prurigo nodularis. Dupilumab is a biologic that inhibits Th2-mediated inflammation and has been successfully used to treat a variety of dermatologic disorders. Dupilumab has revolutionized the management of PN, with recent clinical trials showing its efficacy in treating both pruritus and prurigo nodules, as well as improving quality of life. It has a favorable safety profile and is well tolerated. Other novel treatments are also currently under investigation for the treatment of PN, with early studies reporting promising results.
UNASSIGNED: Dupilumab is becoming the drug of choice for the treatment of PN and may also be effective in treating patients with systemic underlying causes of their PN, although more studies are needed to assess this. Trials evaluating the long-term efficacy and durability of dupilumab in PN are also of interest.
UNASSIGNED: In this article, we discuss the use of dupilumab for adult patients with prurigo nodularis. Dupilumab is a biologic that inhibits Th2-mediated inflammation and has been successfully used to treat a variety of dermatologic disorders. Dupilumab has revolutionized the management of PN, with recent clinical trials showing its efficacy in treating both pruritus and prurigo nodules, as well as improving quality of life. It has a favorable safety profile and is well tolerated. Other novel treatments are also currently under investigation for the treatment of PN, with early studies reporting promising results.
UNASSIGNED: Dupilumab is becoming the drug of choice for the treatment of PN and may also be effective in treating patients with systemic underlying causes of their PN, although more studies are needed to assess this. Trials evaluating the long-term efficacy and durability of dupilumab in PN are also of interest.
摘要：
■结节性痒疹（PN）是一种慢性炎症性皮肤病，表现为瘙痒和角化过度结节。这些症状影响患者的生活质量和心理健康。治疗结节性痒疹很有挑战性，和许多可用的局部和全身疗法具有有限的疗效和无数的不良反应。
■在本文中，我们讨论了dupilumab在结节性痒疹成年患者中的应用.Dupilumab是一种抑制Th2介导的炎症的生物制剂，已成功用于治疗多种皮肤病。Dupilumab彻底改变了PN的管理，最近的临床试验显示其治疗瘙痒和瘙痒结节的疗效，以及提高生活质量。它具有良好的安全性和耐受性。其他新的治疗方法目前也在研究中，用于治疗PN。早期研究报告了有希望的结果。
■Dupilumab正在成为治疗PN的首选药物，也可能有效治疗患有全身性PN的潜在原因的患者。尽管需要更多的研究来评估这一点。评估dupilumab在PN中的长期疗效和耐久性的试验也是感兴趣的。
■在本文中，我们讨论了dupilumab在结节性痒疹成年患者中的应用.Dupilumab是一种抑制Th2介导的炎症的生物制剂，已成功用于治疗多种皮肤病。Dupilumab彻底改变了PN的管理，最近的临床试验显示其治疗瘙痒和瘙痒结节的疗效，以及提高生活质量。它具有良好的安全性和耐受性。其他新的治疗方法目前也在研究中，用于治疗PN。早期研究报告了有希望的结果。
■Dupilumab正在成为治疗PN的首选药物，也可能有效治疗患有全身性PN的潜在原因的患者。尽管需要更多的研究来评估这一点。评估dupilumab在PN中的长期疗效和耐久性的试验也是感兴趣的。
